Product Description
PDHK inhibitor; Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. (Sourced from: https://www.akrospharma.com/pipeline-products/pipe/)
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Akros Pharma
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Heart Failure, Chronic|Heart Failure, Systolic
Phase 1: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02106585 |
AT251-U-13-001 | P1 |
Completed |
Type 2 Diabetes |
2014-08-01 |
2019-03-20 |
Treatments |
|
NCT03789643 |
RELIEF-PAH | P2 |
Withdrawn |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2021-03-01 |
18% |
2019-05-06 |
Patient Enrollment|Treatments|Trial Status |
2017-005093-19 |
BEAT-CHF | P2 |
Terminated |
Heart Failure, Chronic|Heart Failure, Systolic |
2019-04-29 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|